Loading...

AdAlta Limited

1AD.AXASX
Healthcare
Biotechnology
A$0.002
A$0.00(0.00%)

AdAlta Limited (1AD.AX) Company Profile & Overview

Explore AdAlta Limited’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

AdAlta Limited (1AD.AX) Company Profile & Overview

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company's lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has collaborative partnerships with GE Healthcare to discover i-bodies that bind to granzyme B; and Carina Biotech Pty Ltd. to develop CAR-T cell products against various solid tumor antigens. AdAlta Limited was incorporated in 2006 and is headquartered in Bundoora, Australia.

SectorHealthcare
IndustryBiotechnology
CEOTimothy Charles Oldham BSc(Hons), LLB(Hons),

Contact Information

61394795159
Shop 14 330 Collins St, Melbourne, VIC, 3083

Company Facts

9 Employees
IPO DateAug 22, 2016
CountryAU
Actively Trading

Frequently Asked Questions

;